Let’s look at the key reasons that are pushing 10x Genomics Inc (TXG) to new highs

10x Genomics Inc (NASDAQ: TXG) kicked off on Monday, up 2.14% from the previous trading day, before settling in for the closing price of $8.43. Over the past 52 weeks, TXG has traded in a range of $6.78-$28.25.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Healthcare Sector giant saw their annual sales surged by 21.90% over the last five years. While this was happening, its average annual earnings per share was recorded -0.01%. With a float of $101.85 million, this company’s outstanding shares have now reached $108.24 million.

The firm has a total of 1306 workers. Let’s measure their productivity. In terms of profitability, gross margin is 68.73%, operating margin of -31.51%, and the pretax margin is -29.09%.

10x Genomics Inc (TXG) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Health Information Services Industry. The insider ownership of 10x Genomics Inc is 17.29%, while institutional ownership is 86.03%. The most recent insider transaction that took place on Feb 28 ’25, was worth 84,393. In this transaction Chief Executive Officer of this company sold 7,942 shares at a rate of $10.63, taking the stock ownership to the 871,540 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director, CEO proposed sale 7,942 for $10.57, making the entire transaction worth $83,947.

10x Genomics Inc (TXG) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around -0.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.93% during the next five years compared to -36.10% drop over the previous five years of trading.

10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators

Take a look at 10x Genomics Inc’s (TXG) current performance indicators. Last quarter, stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.74.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.18 in one year’s time.

Technical Analysis of 10x Genomics Inc (TXG)

Analysing the last 5-days average volume posted by the [10x Genomics Inc, TXG], we can find that recorded value of 2.98 million was lower than the volume posted last year of 3.13 million. As of the previous 9 days, the stock’s Stochastic %D was 74.01%. Additionally, its Average True Range was 0.57.

During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 17.48%, which indicates a significant decrease from 94.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.88% in the past 14 days, which was lower than the 75.83% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $9.32, while its 200-day Moving Average is $15.33. Now, the first resistance to watch is $8.75. This is followed by the second major resistance level at $8.88. The third major resistance level sits at $9.14. If the price goes on to break the first support level at $8.36, it is likely to go to the next support level at $8.10. Now, if the price goes above the second support level, the third support stands at $7.97.

10x Genomics Inc (NASDAQ: TXG) Key Stats

The company with the Market Capitalisation of 1.06 billion has total of 122,302K Shares Outstanding. Its annual sales at the moment are 610,790 K in contrast with the sum of -182,630 K annual income. Company’s last quarter sales were recorded 165,020 K and last quarter income was -49,030 K.